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OBJECTIVES: Condoliase, an enzyme that specifically degrades glycosaminogly-
cans, main constituents of the nucleus pulposus, and reduces the compressions on 
nerves, can serve as a less-invasive curative treatment for patients with lumbar disc 
herniation and is expected to reduce associated medical cost due to shortened hos-
pital stays. This study aims to evaluate the cost-effectiveness of the treatment with 
condoliase compared with conventional surgical therapy in the Japanese healthcare 
system. METHODS: A Markov model was developed to estimate quality-adjusted 
life year (QALY) and associated costs over 1 year. QOL scores were converted from 
corresponding Oswestry Disability Index (ODI). ODI of condoliase group came from 
the results of a phase 3, multicenter, double-blind, randomized placebo-controlled 
study conducted in Japan. ODI of surgery group was estimated from the values 
obtained from published literatures. The risk of re-operation after treatment was 
considered during calculation. Surgical treatment costs and re-operation costs were 
collected and estimated using a Japanese administrative claims database (Japan 
Medical Data Center, JMDC). Payer perspective was adopted, and discounting was 
not applied due to the short timeframe of the analysis. One-way sensitivity analysis 
was performed to assess the impact of parameter uncertainty on the model’s con-
clusion. RESULTS: Average cost and effectiveness gained per patient for condoliase 
group and surgery group were 385,344 JPY vs. 798,919 JPY, 0.694 QALY vs. 0.685 QALY, 
respectively, meaning condoliase group was dominant compared to surgery group. 
One-way sensitivity analysis showed the robustness of this result. CONCLUSIONS: 
From the payer perspective, treatment with condoliase for patients with lumbar disc 
herniation in Japan is expected to reduce medical costs compared to conventional 
surgery treatment even taking into account the uncertainties.
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OBJECTIVES: Rheumatoid Arthritis (RA) destroys synovial joints and generates 
pain. Its prevalence in Chile has been estimated to be 0.46% (IC 95% 0.24-0.8). 
Available drugs for treatment include conventional synthetic Disease-Modifying 
Antirheumatic Drugs (csDMARDs), biological therapies and a new drug approved for 
treatment after failure of csDMARDs: tofacitinib. The aim of this study is to compare 
the costs-effectiveness of tofacitinib relative to biological therapies as an initial 
treatment in adults with RA after failure of methotrexate in Chile. METHODS: A 
simulation model of individual patients compared two treatment sequences for RA: 
tofacitinib vs biological therapy as initial medications; always assuming a combina-
tion therapy with methotrexate; biological therapies validated with rheumatologists 
and included in the model were etanercept, infliximab, tocilizumab, adalimumab, 
rituximab and salvage therapy (defined by experts). The characteristics of the 
patient included: age, weight, initial HAQ score, and clinical response to short and 
long term treatment. HAQ scores were used to calculate utilities, measured in QALYs 
based on literature information. All costs were obtained from public tenders and 
official reports from Chilean Ministry of Health. The analysis was made from third 
payer perspective with one, five, ten years and lifetime horizon. Annual discount 
rate was 3% for costs and outcomes. Results are expressed in USD2014 (US$1 = 
CLP$600) RESULTS: Total costs, for year one of treatment was US$9,627 starting the 
sequence with tofacitinib and US$11,638 starting with etanercept; obtained HAQ-
QALYs were 0.76 and 0.68, respectively. The total cost of the sequence strategy for 
lifetime horizon initiating with tofacitinib, was US$236,373 compared to the treat-
ment with biological therapy: US$259,403 with a difference of 0.62HAQ-QALY for 
utility. The costs included the drug, administration and health care. CONCLUSIONS: 
The sequence of treatment initiating with tofacitinib for RA Arthritis is a dominant 
strategy compared to biological therapies used in Chile. Net savings with this drug 
is US$35,006
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OBJECTIVES: Primary Total Hip Arthroplasty(THA) provides quality of life to 
patients and is cost-effective. Improvements to implant life have focused on the 
bearing surface with ceramic-on-polyethylene (CoP) bearing use growing rapidly 
due to evidence of longer implant life. We sought to determine if the increased 
CoP cost over the metal-on-polyethylene (MoP) provides enough benefit through 
lower revision rate to justify its utilization. METHODS: A Markov decision model 
was designed to determine the reduction in CoP 20-year revision rate required 
to make this implant cost-effective compared to MoP. Premier’s 2012 Research 
Database provided hospitalization costs for primary and revision surgeries. The 
Orthopedic Research Network (ORN) provided aggregated implant purchase price 
information. The HealthEast Joint Registry was the source of the MoP revision rate 
used for comparison. At each 10-year age increment/bearing cost condition, the 
CoP revision rate was varied until the lifetime costs were equal for the 2 different 
bearings. RESULTS: The sample included 20,398 patients aged 45-89+ from 475 US 
hospitals with identified bearing surfaces. CoP vs. MoP surface cost differences were 
$325+/-$177(p= 0.014) and $1,003+/-$710(p= 0.003), respectively, based on unadjusted 
and adjusted analysis of Premier data. ORN reports indicated a $600 difference 
in 2012. Revision costs were $23,628+/-$385 on 8,566 patients. HealthEast’s data 
indicates a 20-year MoP revision rate of 14.5/100THAs. An inflection in the revision 
scores (and changes) using results of a mixed treatment comparison (first 6 months) 
and data from long-term extension trials (later treatment periods). Where available, 
meta-analysis data were used to estimate adverse events incidence, followed by 
individual trial data and registry estimates. Canadian data from published sources 
were used to derive healthcare resource utilization costs and EuroQol-5D scores 
from HAQ-DI scores. All costs were estimated in 2014 Canadian dollars. Probabilistic 
and one-way sensitivity analyses were completed on analytical horizon, event rates, 
and efficacy thresholds. RESULTS: After running the model for 100,000 simula-
tions of moderate to severe RA patients, the treatment arm including tofacitinib 
had lifetime costs of $298,434 with 8.17 QALYs. Comparatively, the treatment arm 
excluding tofacitinib had a lifetime cost of $305,158 with 7.88 QALYs. Therefore, a 
treatment strategy including tofacitinib is dominant with lower costs and greater 
effectiveness. One-way and probabilistic sensitivity analysis reflected the robust-
ness of these results. CONCLUSIONS: The inclusion of tofacitinib into the treatment 
strategy for moderate to severe RA is a dominant strategy in Canada (lower cost 
and increased QALYs).
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory condition with 
significant economic burden. Tofacitinib is an oral Janus kinase inhibitor indicated 
in the US for the treatment of moderate to severe RA in patients with inadequate 
response to methotrexate. Given the similarity of indications across available 
therapies, economic evaluation of alternate treatment strategies could inform 
US formulary decisions. We estimated incremental cost-effectiveness ratios of 
tofacitinib after methotrexate failure in a treatment sequence compared with 
a similar sequence without tofacitinib from a US third-party payer’s perspec-
tive. METHODS: The model estimated costs and outcomes of RA treatment 
with a pre-specified “treatment sequence” (sequential methotrexate, tofacitinib, 
adalimumab, abatacept, tocilizumab, rituximab) versus a “comparator sequence” 
(sequential methotrexate, etanercept, adalimumab, abatacept, tocilizumab, rituxi-
mab). Alternative sequences were considered. Efficacy was assessed by Health 
Assessment Questionnaire (HAQ) and compared using mixed treatment com-
parison and data from long-term extension trials. Adverse event data were from 
published meta-analyses and trials of tofacitinib and comparators. Patient char-
acteristics were based on tofacitinib clinical trials (NCT00856544; NCT00847613; 
NCT00853385). RA-related costs were from published data mapping HAQ onto 
healthcare resource utilization in US patients with RA. Indirect costs were not con-
sidered. RESULTS: From a US third-party payer’s perspective, the predicted lifetime 
cost of “treatment sequence” including tofacitinib was $509,047 versus $546,860 for 
“comparator sequence” without tofacitinib, with the difference primarily driven by 
drug cost. The “treatment sequence” with tofacitinib resulted in an additional 0.11 
quality-adjusted life years versus “comparator sequence.” Probabilistic sensitivity 
analysis suggested the probability that tofacitinib is cost-effective as second-line 
therapy is 64.0% at a threshold of $100,000. CONCLUSIONS: Our model suggests 
that including tofacitinib as second-line therapy following methotrexate failure 
is a cost-effective alternative versus a “comparator sequence” without tofacitinib. 
Sensitivity analysis reiterated robustness of the findings and cost-effectiveness 
of including tofacitinib. Results of alternate treatment sequence comparisons 
were similar.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disorder of the 
musculoskeletal system. After inadequate response (IR) to anti-tumor necrosis fac-
tor (anti-TNF) treatments, the clinical and economic value of alternative biologic 
agents is unclear. We sought to estimate the cost-effectiveness of tocilizumab 
versus abatacept from a U.S. payer perspective. METHODS: We constructed a 
treatment-regimen based cohort model with a lifetime horizon. The model evalu-
ated the treatment comparison of tocilizumab (162mg every other week with 
escalation to weekly for inadequate responders) vs. abatacept (125mg, weekly). In 
this comparison, treatment initiation was followed by a certolizumab-tofacitinib-
rituximab-palliative care sequence. Treatment response rates were applied every 
6 months. Health related quality of life was mapped to the health assessment 
questionnaire (HAQ) for RA. Mortality was modelled allowing for both non-RA and 
RA-specific mortality predicted by the HAQ. Costs were derived from published 
sources and included drug treatment, monitoring, and direct medical resource 
utilization. Costs and QALYs were discounted at 3%. Sensitivity analyses were 
performed to test the robustness of the model results. RESULTS: Comparing the 
two initial treatments, tocilizumab dominated abatacept yielding better outcomes 
and fewer costs. Probabilistic sensitivity analyses indicated substantial uncer-
tainty, yet the mean estimates remained consistent with the deterministic results. 
Tociluzumab had an 89% probability of being cost-effective at $50,000/QALY. The 
one-way sensitivity analysis indicated that the parameters related to baseline 
HAQ and improvement in the ACR 50 and 70 rates had the most impact on model 
results. CONCLUSIONS: Management of TNF-IR patients with RA represents a 
challenge for the health care system. Compared to abatacept, tocilizumab appears 
to represent a lower cost treatment option with improved outcomes. However, 
with the attendant uncertainty, head-to-head trials of these agents may be 
warranted.
